NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
Emerging Science (Late-Breaker Equivalent) Abstract To Be Presented At 5:30PM Local Time Highlights Phase 2 PARADIGM Outcomes
CAMBRIDGE, Mass., April 12, 2024 /PRNewswire/ — NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing novel treatments for severe neurodegenerative diseases, announces lead author Merit Cudkowicz, Chair of Neurology at Massachusetts General Hospital, and Julieanne Dorn Professor of Neurology at Harvard Medical School, will be presenting data from the PARADIGM Phase 2 study of PrimeC during an Emerging Science session (equivalent to Late Breaker) at the American Academy of Neurology Annual Meeting.